Introduction
Induction of labour is a relatively common procedure nowadays. It has been practiced since 16th century. In the past, induction of labour was performed for delivery of a dead fetus. With time indications for induction of labour have changed. Presently it is being used for benefits of the mother or the fetus. The World Health Organization defines 'induction of labour' as stimulation of contractions before the spontaneous onset of labour to achieve vaginal delivery 1 .
Induction is indicated when the benefits to the mother or the fetus outweigh that of continuing the pregnancy. The most common indication for induction worldwide is post datism, others are premature rupture of membranes, preeclampsia, intrauterine fetal death, intrauterine growth restriction, fetal congenital anomaly, gestational diabetes mellitus, potential fetal compromise 2, 3 .
Methods of induction of labour that can ripen the cervix in a short period of time play a very important role. Worldwide the most common method for induction of labour is the pharmacological method using prostaglandin E2 gel. The focus for induction of labour has shifted from the earlier oxytocin drips to prostaglandin E2 gel. Prostaglandin E2 gel is most commonly used for cervical ripening and induction of labour. However, it is expensive and requires stringent maintenance criteria like cold storage between 2-8 degree Celsius. Prostaglandin E2 has a very short half life even when maintained at the temperatures required. PGE2 has to be administered by the intracervical route. As the rate of absorption and its efficacy is dependent on many confounding factors, the results vary from failure of action to hypertonic uterine contractions and erratic response to the drug.
Recently it was found that, in patients who were administered with prostaglandin E1 (PGE1) analogue for its protective property against peptic ulcer, showed a dramatic increase in the rate of abortions and premature deliveries. This has lead to the exploration of a possibility of using PGE1 analogues for cervical ripening and induction of labour. As a result of the ongoing research and because of proven safety and efficacy 4 However, reliable evidence is lacking regarding the most appropriate route of administration and the dose of PGE1 and also whether it has any advantages over PGE2, which is the most commonly used prostaglandin for induction. Hence, the comparison between the efficacy and safety of intracervical PGE2 and intravaginal PGE1 for cervical ripening and induction of full term labour is the subject of this study.
Materials and Methods
This was an analytical observational study which was carried out in the Department of Obstetrics and Gynaecology, at a tertiary reference centre after due approval from the Institutional Ethics Committee. Patients who were induced with intra cervical PGE2 or intra vaginal PGE1 for various indications and fulfilled the inclusion and exclusion criteria were included. All admitted patients undergoing induction of labour underwent ultrasonography, non stress test was performed to assess fetal well being and Pre induction Bishops score and cervical assessment. The Study consisted of 200 patients who were divided into 2 groups (100 each) and each 100 patients were given prostaglandin E1 analogue (PGE1) and100 patients in prostaglandin E2 analogue (PGE2) respectively. Group A-In the prostaglandin E1 analogue (PGE1), one dose of intravaginal PGE1 followed by a second dose after 4 hours. Each woman was administered 25 µg tablet of prostaglandin E1 analogue (PGE1), in the posterior fornix of the vagina under aseptic condition. After every dose, 4 hourly Bishop Score was re-evaluated and if score remained <6, reinstallation (25 µg) was done depending upon on the response, the patients received up to maximum 3 doses. Group B-The first dose of Prostaglandin E2 analogue (PGE2) which is 0.5 mg was given intracervical (gel). After 6 hours Bishop's score was reassessed. If the Bishop's score remained < 6, Second dose was given. Maximum of two doses were given. Using sterile technique, the tip of a prefilled syringe containing 0.5 mg of PGE2 analogue was instilled intracervically, the gel was deposited just below the internal cervical os, and the women were kept in a recumbent position for at least 30 minutes. 
Results
According to this data, out of 100 cases 58 were primigravida and 42 were multigravida in PGE1 group and out of 100 cases in PGE2 group, 52 were primigravida and 48 were multigravida but the difference was not significant. 9 out of 100 women in PGE1 group and 11 out of 100 women in PGE2 were 18-20 years, 40 out 100 women in PGE1 and 35 out of 100 women in PGE2 group were 21-25 years, 40 out of 100 women in PGE1 group and 38 out of 100 women were 26-30 years and 11 out of 100 women in PGE1 group and 16 out of 100 women in PGE2 group were 31-36, the difference was not significant. The analysis of the gestational age in both the groups showed that there was no statistically significant difference in the gestational ages of the 2 groups. The analysis of the data for reason of induction showed that in 28.0% of cases indication of induction was post date pregnancy among PGE1 group which was comparable with 32.0% of cases among PGE2 group and difference was statistically not significant. 29.0% of cases showed indication of induction as PROM among PGE1 group which was more as compared to 23.0% of cases among PGE2 group but difference was statistically not significant. In PGE2 group Bishop's score at the end of 6 hrs for 9 out of 100 cases was between 0-4, for 21 cases was >4 to <6 and for 70 cases was ≥6 but the difference was statistically not significant. At the end of 6 hrs, 70% cases shows Bishop's score ≥6. Mean duration of Interval time of induction to onset of labour pains and uterine activity was 3.51 hrs in PGE1 group which was significantly less as compared to 5.00 hrs among PGE2 group. According to this observation, 25.0% of the cases of PGE1 group required oxytocin for labour augmentation which was significantly less as compared to 41.0% of the cases among PGE2 group. Figure 2: Profile Of Oxytocin Between Two Groups According to this study, 1 dose required for cervical ripening in 70% of cases which was same among both the groups and difference was statistically not significant. 2 doses required for 18 cases in PGE1 group and 17 cases in PGE2 group. In PGE1 group 6 cases required 3 doses for cervical ripening. Comparison of mean induction to delivery interval between two groups showed that it was 8.39 hrs among PGE1 group which was significantly less as compared to 11.61 hrs among PGE2 group.
87.0% of cases of PGE1 group delivered within ≤ 12 hrs after induction which was significantly more as compared to 66.0% of cases among PGE2 group. Amongst PGE1 group, 77.0% of the cases delivered by normal vaginal delivery which was more as compared to 69.0% of the cases among PGE2 group but difference was not significant. 16 .0% of the cases required LSCS among PGE1 group which was less as compared to 26.0% of the cases among PGE2 group but difference was not significant.7.0% of the cases delivered by instrumental delivery among PGE1 group which was comparable with 5.0% of the cases among PGE2 group and difference was statistically not significant. 10.3% of cases had hyperstimulation in primi which was more as compared to 2.4% of cases in multi among PGE1 group but difference was statistically not significant while 3.8% of cases had hyperstimulation in primi which was comparable with 2.1% of cases in multi among PGE2 group and difference was statistically not significant.
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In this study 4.0% of cases used tocolytics among PGE1 group which was comparable with 2.0% of cases among PGE2 group and difference was statistically not significant. While 75.0% of cases required LSCS who used tocolytics among PGE1 group which was more as compared to 50.0% of cases among PGE2 group but difference was statistically not significant. 
PGE2
The neonatal outcome was also studied in these cases. 9.0% of babies had passed meconium among PGE1 group which was comparable to 5.0% of the cases among PGE2 group and the difference was not significant. Whereas Amongst PGE1 group 3% babies developed birth asphyxia in comparison to 3% cases of PGE2 group, 3% babies of PGE1 group developed meconium aspiration syndrome in comparison to 2% cases of PGE2 group. There was no case of IUD or HIE.
Figure 5 :
Profile of Baby Record between two groups 14.0% babies of the cases of PGE1 group required NICU/TCU admission which was more as compared to 7.0% babies of the cases among PGE2 group but the difference was not significant At 1minute, mean APGAR score was 7.36 among PGE1 group which was comparable to 7.33 among PGE2 group and the difference was not significant. At the end of 5 minutes also mean APGAR score were comparable and difference was not significant. The analysis of mean body weights in both the groups showed that mean baby weight was 2628.80 gms among PGE1 group which was comparable with 2729.60 gms among PGE2 group and difference was statistically not significant. It was further found that, 91.4% of cases with dose 1 were reactive in primi which were less as compared to 97.6% of cases in multi among PGE1 group but difference was statistically not significant. 1.7% of cases with dose 3 were Non reactive in primi which were comparable with 2.4% of cases in multi among PGE1 group and difference was statistically not significant. Finally, 96.2% of cases with dose 1 were reactive in primi which were comparable with 97.9% of cases in multi among PGE2 group and difference was statistically not significant. None of cases with dose 2 were Non reactive in primi which were less as compared to 4.2% of cases in multi among PGE2 group but difference was statistically not significant. Whereas in PGE2 multigravida, 96.2% of cases with dose 1 were reactive in primi which were comparable with 97.9% of cases in multi among PGE2 group and difference was statistically not significant. None of cases with dose 2 were Non reactive in primi which were less as compared to 4.2% of cases in multi among PGE2 group but difference was statistically not significant. Finally the analysis of cost effectiveness showed that mean cost was 11.07 Rs among PGE1 group which was significantly less as compared to 336.70 Rs among PGE2 group. . In the present study, cervical ripening was observed in 70 cases after 1 dose, in 18 cases after 2 doses and in 6 cases after 3 doses in PGE1 group. In PGE2 group cervical ripening was seen in 70 cases after 1 dose and in 17 cases after 2 doses. In the present study, 84% of women induced with PGE1, out of these 79.3% women were primigravida and 85% multigravida delivered vaginally within 12 hrs of induction. As compared to 59% of women who were induced with PGE2, out of these 55.7% were primigravida and 62.5% multigravida had delivered vaginally within 12 hrs of induction. PGE1 group had more deliveries in less than 12 hours compared to PGE2 which had more deliveries in the time frame of 12-24 hrs. Similar results were observed in study conducted by Dara Aruna Kumari et al 12 . The Cochrane reviewers Hofmeyr and Gumezoglu 13 observed that use of PGE1 results in higher incidence of vaginal delivery within 24 hours of application and a reduced need for oxytocin augmentation.
In the present study, the caesarean section rate was more in women who were induced with PGE2. This result was similar to the study conducted by Kundodyiwa et al 14 . The caesarean section rate was observed high among primigravida in both the groups. 18.9% of primigravida women induced with PGE1 were delivered by caesarean section and 26.9% underwent caesarean in the PGE2 group. Among the multigravida, 11.9% women in the PGE1 group and 25% in the PGE2 group required caesarean section. The proportion of women who underwent caesarean section for fetal distress was higher in the PGE1 group as compared to that in the PGE2 group. But these differences were not significant. These findings were similar with the results of the metaanalysis reported by Sanchez-Ramos et al 15 .
In this study, 7% of cases of PGE1 group and 3% of cases of PGE2 group had developed uterine hyperstimulation. In such cases, tocolytics were used for 4% of cases in PGE1 group and 2% of cases in PGE2 group. Despite the treatment 3% of cases of PGE1 and 1% of cases of PGE2 group required LSCS in view of fetal distress. A retrospective study of case notes (n=3099) observed that after tocolytics treatment in the cases with uterine hyperstimulation, there was an improvement regardless of hyperstimulation patterns. Three cases required caesarean section and there were no postpartum complications 16 . .
Wing et al 17 .while comparing 25 microgram vaginal PGE1 with intravaginal PGE2 gel observed that the neonatal outcome between the two groups was comparable and there were no significant differences in the birth weight, 1 or 5 min. APGAR scores, required for neonatal resuscitation or admission to neonatal intensive care unit. Meconium passage occurred in 9% of babies born to women in PGE1 group as compared to 5% of babies in PGE2 group, although meconium aspiration syndrome occurred only in 4% of the babies, in the study. Thus PGE1 in the dose of 25 microgram is safe and there is no significant difference in the incidence of intrapartum fetal complications in the form of abnormal FHR patterns and meconium passage as compared to PGE2. Mozurkewich EL et al 18 .found meconium stained liquor were more common with PGE1 than with PGE2. In the present study, the average cost of therapy was Rs11.07/-per women in the PGE1 group compared to Rs 336.70/-in the PGE2 group. According to market values of both the prostaglandin analogues, the average cost of therapy of PGE2 group was significantly higher than that of the PGE1 group, so patients usually prefer PGE1 over PGE2. Similar results were observed by Van Barren et al 19 and Beckmann M et al 20 . In this study the cost of therapy was significantly less in the PGE1 group (Rs 9/-vs. Rs 406.57/-respectively) per woman.
Conclusion
Both PGE1 and PGE2 are safe for induction of labor. Though maternal and fetal outcomes were comparable in both the groups Induction to delivery time, need for LSCS and overall cost was found to be less in PGE1 group hence our study concludes that intravaginal PGE1 is more efficacious and cost-effective in comparison to intracervical PGE2.
